1. Scrip
  2. >>Focus On Asia
  3. >>India

Why India's generics program may have few private sector takers

 
• By Anju Ghangurde

An Indian government tender for more than 280 drugs under its ambitious "Jan Aushadhi" cut-price medicines program is expected to generate limited interest from leading private players, if the early responses of a number of experts is anything to go by.

An Indian government tender for more than 280 drugs under its ambitious "Jan Aushadhi" cut-price medicines program is expected to generate limited interest from leading private players, if the early responses of a number of experts is anything to go by.

Poor last-mile distribution planning, uncertainty over payments and concerns around trade margins are some of the key issues that are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

Indigenization, AI Drive ICMR, Gennova, Zydus Vaccine Efforts In India

 
• By Vibha Ravi

Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis

E-Pharmacies In India: Mind The Data Privacy Gap, Regulatory Deficit

 
• By Anju Ghangurde

Legal and other experts discuss the need to plug data privacy and regulatory gaps and address prescription shortcuts at e-pharmacies. Collaborative models with brick-and-mortar chemists were also proposed.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

More from Focus On Asia

Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC

 
• By Dexter Jie Yan

With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Indigenization, AI Drive ICMR, Gennova, Zydus Vaccine Efforts In India

 
• By Vibha Ravi

Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis